1
00:00:03,000 --> 00:00:06,600
This is Sunday Rounds for 15 November 2026.

2
00:00:06,600 --> 00:00:09,600
Weight loss on GLP-1-based drugs is not only

3
00:00:09,600 --> 00:00:13,267
fat loss. Some of it is lean or muscle mass.

4
00:00:13,267 --> 00:00:16,000
This week, two randomised trials ask how

5
00:00:16,000 --> 00:00:18,400
that loss can be limited.

6
00:00:18,400 --> 00:00:22,067
One adds resistance exercise to tirzepatide.

7
00:00:22,067 --> 00:00:24,933
The other adds the antibody trevogrumab to

8
00:00:24,933 --> 00:00:27,733
semaglutide. Neither describes results in

9
00:00:27,733 --> 00:00:30,100
Indian patients.

10
00:00:30,100 --> 00:00:33,500
A randomised trial in Nature Medicine put

11
00:00:33,500 --> 00:00:36,800
120 adults with overweight or obesity on

12
00:00:36,800 --> 00:00:39,700
tirzepatide. They did thrice-weekly

13
00:00:39,700 --> 00:00:43,267
resistance exercise or usual activities for

14
00:00:43,267 --> 00:00:46,400
40 weeks. Weight loss was similar:

15
00:00:46,400 --> 00:00:50,867
-22.61 kg alone and -22.28 kg with exercise.

16
00:00:50,867 --> 00:00:54,100
Lean soft tissue mass loss was -4.67 kg

17
00:00:54,100 --> 00:00:57,667
alone and -3.57 kg with exercise, a 1.09 kg

18
00:00:57,667 --> 00:01:01,233
difference (95% CI 0.43-1.75 kg).

19
00:01:01,233 --> 00:01:04,533
Strength fell with tirzepatide alone and

20
00:01:04,533 --> 00:01:08,000
rose with exercise. Hard clinical outcomes

21
00:01:08,000 --> 00:01:10,867
were not reported.

22
00:01:10,867 --> 00:01:13,867
COURAGE was a phase 2, double-blind,

23
00:01:13,867 --> 00:01:17,067
placebo-controlled trial of 975 adults with

24
00:01:17,067 --> 00:01:20,267
obesity at 60 US sites, funded by Regeneron

25
00:01:20,267 --> 00:01:22,600
Pharmaceuticals, Inc.

26
00:01:22,600 --> 00:01:25,367
At 26 weeks, lean mass fell 6.6% with

27
00:01:25,367 --> 00:01:28,000
semaglutide plus placebo.

28
00:01:28,000 --> 00:01:31,067
Differences versus placebo were +3.1% for

29
00:01:31,067 --> 00:01:34,133
trevogrumab 200 mg, +2.7% for 400 mg, and

30
00:01:34,133 --> 00:01:37,333
+4.5% for 400 mg plus garetosmab.

31
00:01:37,333 --> 00:01:40,467
The combination had serious adverse events

32
00:01:40,467 --> 00:01:43,767
in 9% and discontinuations in 32%.

33
00:01:43,767 --> 00:01:47,700
Function results were not reported.

34
00:01:47,700 --> 00:01:50,167
Both randomised trials found that the add-on

35
00:01:50,167 --> 00:01:52,167
reduced the fall in lean mass during

36
00:01:52,167 --> 00:01:54,233
incretin-based weight loss.

37
00:01:54,233 --> 00:01:56,400
Both used surrogate measures.

38
00:01:56,400 --> 00:01:59,033
Neither gives hard clinical outcomes.

39
00:01:59,033 --> 00:02:01,333
They differ in drug, comparator, duration

40
00:02:01,333 --> 00:02:03,633
and units, so they should not be compared

41
00:02:03,633 --> 00:02:05,933
head to head. The exercise trial measured

42
00:02:05,933 --> 00:02:07,733
strength, and it rose.

43
00:02:07,733 --> 00:02:10,633
COURAGE gave no physical function results.

44
00:02:10,633 --> 00:02:13,100
On safety, COURAGE reported a high incidence

45
00:02:13,100 --> 00:02:14,733
of serious adverse events and

46
00:02:14,733 --> 00:02:17,200
discontinuations, and more muscle spasms, in

47
00:02:17,200 --> 00:02:19,000
the combination group.

48
00:02:19,000 --> 00:02:21,467
Its authors say the combination did not have

49
00:02:21,467 --> 00:02:23,967
favourable safety and tolerability.

50
00:02:23,967 --> 00:02:26,433
The exercise abstract gives no adverse event

51
00:02:26,433 --> 00:02:28,667
details. On fat and weight, the exercise

52
00:02:28,667 --> 00:02:31,333
trial found no significant difference.

53
00:02:31,333 --> 00:02:33,800
In COURAGE part A, fat mass loss was greater

54
00:02:33,800 --> 00:02:37,333
with trevogrumab 400 mg and the combination.

55
00:02:37,333 --> 00:02:39,867
Neither report shows whether less lean mass

56
00:02:39,867 --> 00:02:42,333
loss means better function, fewer falls or

57
00:02:42,333 --> 00:02:44,700
fractures, or less disability.

58
00:02:44,700 --> 00:02:47,167
The exercise report does not show that the

59
00:02:47,167 --> 00:02:50,000
1.09 kg difference matters clinically.

60
00:02:50,000 --> 00:02:52,467
It also does not say what happens after 40

61
00:02:52,467 --> 00:02:55,067
weeks, or after tirzepatide stops.

62
00:02:55,067 --> 00:02:57,600
The abstract does not describe how exercise

63
00:02:57,600 --> 00:02:59,900
was delivered and supervised, or report

64
00:02:59,900 --> 00:03:02,300
funding, blinding, drop-outs, age, sex or

65
00:03:02,300 --> 00:03:04,833
diabetes status. For COURAGE, the lean mass

66
00:03:04,833 --> 00:03:07,133
method, withdrawal period and MRI thigh

67
00:03:07,133 --> 00:03:09,267
substudy are not reported.

68
00:03:09,267 --> 00:03:11,500
No results by ethnicity are given, and

69
00:03:11,500 --> 00:03:14,500
neither report describes Indian patients.

70
00:03:14,500 --> 00:03:17,033
It is unclear whether the garetosmab safety

71
00:03:17,033 --> 00:03:20,367
problems can be explained or avoided.

72
00:03:20,367 --> 00:03:23,200
The exercise trial gives the more usable

73
00:03:23,200 --> 00:03:25,767
message. In adults on tirzepatide, a

74
00:03:25,767 --> 00:03:28,600
structured resistance exercise programme

75
00:03:28,600 --> 00:03:31,567
reduced lean soft tissue loss and improved

76
00:03:31,567 --> 00:03:34,633
strength, with no significant difference in

77
00:03:34,633 --> 00:03:37,033
weight or fat mass loss.

78
00:03:37,033 --> 00:03:40,167
This supports discussing resistance exercise

79
00:03:40,167 --> 00:03:42,867
as part of obesity care alongside drug

80
00:03:42,867 --> 00:03:46,000
treatment. Advice for any individual patient

81
00:03:46,000 --> 00:03:48,567
should consider their conditions and

82
00:03:48,567 --> 00:03:52,133
fitness. The antibody results are early.

83
00:03:52,133 --> 00:03:55,267
Trevogrumab alone is described as a proof of

84
00:03:55,267 --> 00:03:58,033
concept from a phase 2 trial.

85
00:03:58,033 --> 00:04:01,100
Benefit in daily life is not yet shown, and

86
00:04:01,100 --> 00:04:04,233
the garetosmab combination lacked favourable

87
00:04:04,233 --> 00:04:06,633
safety and tolerability.

88
00:04:06,633 --> 00:04:09,967
For both trials, read the full paper.

89
00:04:09,967 --> 00:04:14,133
Wait for trials with functional outcomes.

90
00:04:14,133 --> 00:04:16,300
Every report, with its source, is on

91
00:04:16,300 --> 00:04:18,100
diabesityrounds.com.

92
00:04:18,100 --> 00:04:20,967
The slides are free to use in your teaching,

93
00:04:20,967 --> 00:04:22,833
with credit.
